We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App

Groundbreaking Molecular Diagnostic Kit to Provide Lyme Disease Detection in Minutes

By LabMedica International staff writers
Posted on 31 May 2024
Print article
Image: Molecular PCR-grade detection of Lyme bacteria right at the tick bite (Photo courtesy of En Carta Diagnostics)
Image: Molecular PCR-grade detection of Lyme bacteria right at the tick bite (Photo courtesy of En Carta Diagnostics)

Lyme disease, transmitted through tick bites, is a bacteria-caused illness that impacts 1.2 million individuals annually. The standard methods for diagnosing this disease include clinical examinations, visual evaluations, or immunological tests, all of which depend on the presence of advanced symptoms that might take months or even years to appear. Consequently, many cases remain untreated and undiagnosed early on, complicating treatment and leading to the severe, long-term impacts of Lyme disease. Now, a groundbreaking patented molecular diagnostic kit is poised to provide game-changing autonomous detection of Lyme disease within minutes.

Presently, Lyme disease testing methods aim to identify antibodies produced by the body in reaction to the infection. However, since the development of these antibodies can take several weeks, tests performed soon after infection often yield false negatives. En Carta Diagnostics (Paris, France) has developed a molecular diagnostic platform that effectively addresses this issue. This platform, which utilizes a simple cassette format, provides rapid, point-of-care diagnostics with remarkable accuracy. The underlying technology has been improved over a decade of extensive research and employs aptamers—molecules engineered for their strong binding abilities and high specificity to their target. These aptamers can be customized to detect a wide array of genetic, pathogenic, or veterinary markers, significantly broadening potential applications.

En Carta’s diagnostic technology, which drives their detection kits, has undergone rigorous validation against multiple pathogens and has been tested with real patient samples. The company is now developing a diagnostic kit specifically for Lyme disease that promises to deliver results autonomously in mere minutes. The portable and compact cassette enables test performance quickly and easily by anyone and anywhere. Powered by a smartphone, a user friendly and intuitive app allows for easy result interpretation and integration with healthcare systems. By enabling molecular PCR-grade detection of Lyme bacteria right at the tick bite, the test will eliminate medical wandering often experienced by Lyme patients. In addressing Lyme disease as its first application, the company is responding to the growing urgency of this disease, which is now the most common vector-borne illness in the Northern Hemisphere, affecting 1.2 million people each year.

"Today, we have a very robust platform technology leveraged for accuracy, speed and cost, which are key in the Point-of-Care space,” said Guillaume Horreard, CEO at En Carta. “As a first step, we are focusing on Lyme disease, where the sizeable patient population, accelerated growth of the problem and need for rapid diagnosis following a tick bite make our product indispensable.”

Related Links:
En Carta Diagnostics

Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
POCT Fluorescent Immunoassay Analyzer
Gold Member
All-in-one Molecular Diagnosis System
Panall 8000

Print article


Clinical Chemistry

view channel
Image: The new DxC 500i Clinical Analyzer is an integrated clinical chemistry and immunoassay analyzer (Photo courtesy of Beckman Coulter Diagnostics)

Integrated Chemistry and Immunoassay Analyzer with Extensive Assay Menu Offers Flexibility, Scalability and Data Commutability

As global healthcare systems increasingly shift towards networked laboratory operational models to enhance efficiency and patient access, there is a greater need for innovative solutions tailored to the... Read more


view channel
Image: The Truvian diagnostic platform combines clinical chemistry, immunoassay and hematology testing in a single run (Photo courtesy of Truvian Health)

Automated Benchtop System to Bring Blood Testing To Anyone, Anywhere

Almost all medical decisions are dependent upon laboratory test results, which are essential for disease prevention and the management of chronic illnesses. However, routine blood testing remains limited worldwide.... Read more


view channel
Image: The Simplexa C. auris direct kit is a real-time polymerase chain reaction assay run on the LIAISON MDX instrument (Photo courtesy of Diasorin)

Novel Molecular Test to Help Prevent and Control Multi Drug-Resistant Fungal Pathogen in Healthcare Settings

Candida auris (C. auris) is a rapidly emerging multi drug-resistant fungal pathogen that is commonly found in healthcare environments, where it presents a challenge due to its ability to asymptomatically... Read more


view channel
Image: Color-enhanced scanning electron micrograph showing Salmonella Typhimurium (red) invading cultured human cells (Photo courtesy of Rocky Mountain Laboratories, NIAID, NIH)

AI Identifies Drug-Resistant Typhoid-Like Infection from Microscopy Images within Hours

Antimicrobial resistance is becoming a serious global health concern, making many infections increasingly difficult to treat and limiting available treatment options. This escalation in resistance raises... Read more


view channel
Image: Beckman Coulter will utilize the ALZpath pTau217 antibody to detect key biomarker for Alzheimer\'s disease on its DxI 9000 immunoassay analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter Licenses Alzpath's Proprietary P-tau 217 Antibody to Develop Alzheimer's Blood Test

Cognitive assessments have traditionally been the primary method for diagnosing Alzheimer’s disease, but this approach has its limitations as symptoms become apparent only after significant brain changes... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.